newsfilter
← Latest News
Business Wire·

Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026

Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis